HLS Therapeutics Inc. (HLS.TO)
CAD 4.24
(-0.7%)
CAD 4.24
(-0.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 12.88 Million USD | 4.67% |
| 2022 | 17.99 Million USD | -12.75% |
| 2021 | 25.41 Million USD | 9.55% |
| 2020 | 23.19 Million USD | -22.96% |
| 2019 | 19.74 Million USD | 32.78% |
| 2018 | 20.7 Million USD | -61.48% |
| 2017 | 55.51 Million USD | 4532.11% |
| 2016 | 38.24 Million USD | 49.07% |
| 2015 | -2.46 Million USD | -112.58% |
| 2014 | 20.01 Million USD | 4.97% |
| 2013 | 18.46 Million USD | -36.01% |
| 2012 | 29.19 Million USD | 30.96% |
| 2011 | 22.29 Million USD | 93.34% |
| 2010 | 14.1 Million USD | 4.77% |
| 2009 | 11 Million USD | 27.04% |
| 2008 | 8.66 Million USD | -53.55% |
| 2007 | 18.72 Million USD | 474.33% |
| 2006 | 3.2 Million USD | -48.29% |
| 2005 | 4.29 Million USD | 35.7% |
| 2004 | 4.62 Million USD | -49.14% |
| 2003 | 9.09 Million USD | 61.76% |
| 2002 | 5.62 Million USD | -1.77% |
| 2001 | 5.72 Million USD | 10.94% |
| 2000 | 5.16 Million USD | -23.71% |
| 1999 | 6.76 Million USD | 131.37% |
| 1998 | 2.92 Million USD | 13.11% |
| 1997 | 2.51 Million USD | 83.41% |
| 1996 | 1.4 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 7.28 Million USD | 56.3% |
| 2024 Q1 | 2.58 Million USD | -43.45% |
| 2023 FY | - USD | 4.67% |
| 2023 Q1 | 5.15 Million USD | 11.82% |
| 2023 Q2 | 5.38 Million USD | 4.48% |
| 2023 Q3 | 5.24 Million USD | -2.62% |
| 2023 Q4 | 6.15 Million USD | 17.33% |
| 2022 Q1 | 5.5 Million USD | -2.81% |
| 2022 FY | - USD | -12.75% |
| 2022 Q3 | 5.9 Million USD | 19.51% |
| 2022 Q2 | 4.94 Million USD | -10.26% |
| 2022 Q4 | 4.61 Million USD | -21.93% |
| 2021 Q3 | 7.04 Million USD | 0.93% |
| 2021 Q1 | 4.33 Million USD | -31.55% |
| 2021 FY | - USD | 9.55% |
| 2021 Q2 | 6.98 Million USD | 61.05% |
| 2021 Q4 | 5.66 Million USD | -19.59% |
| 2020 Q3 | 5.2 Million USD | 31.83% |
| 2020 Q4 | 6.33 Million USD | 21.72% |
| 2020 Q2 | 3.94 Million USD | -38.82% |
| 2020 FY | - USD | -22.96% |
| 2020 Q1 | 6.45 Million USD | 19.07% |
| 2019 Q1 | 7.7 Million USD | -28.09% |
| 2019 Q2 | 7.67 Million USD | -0.35% |
| 2019 FY | - USD | 32.78% |
| 2019 Q4 | 5.41 Million USD | -29.42% |
| 2019 Q3 | 7.67 Million USD | 0.01% |
| 2018 Q2 | 19.15 Million USD | 123.35% |
| 2018 FY | - USD | -61.48% |
| 2018 Q4 | 10.7 Million USD | 220.83% |
| 2018 Q3 | -8.86 Million USD | -146.27% |
| 2018 Q1 | 8.57 Million USD | -63.55% |
| 2017 Q1 | -412.42 Thousand USD | -36.19% |
| 2017 FY | - USD | 4532.11% |
| 2017 Q4 | 23.53 Million USD | 5116.01% |
| 2017 Q3 | -469.15 Thousand USD | -19.87% |
| 2017 Q2 | -391.36 Thousand USD | 5.1% |
| 2016 Q3 | -195.47 Thousand USD | 45.61% |
| 2016 FY | - USD | 49.07% |
| 2016 Q2 | -359.41 Thousand USD | 12.14% |
| 2016 Q1 | -409.07 Thousand USD | -212.82% |
| 2016 Q4 | -302.82 Thousand USD | -54.92% |
| 2015 Q2 | -203.01 Thousand USD | 89.19% |
| 2015 Q3 | -412.66 Thousand USD | -103.27% |
| 2015 Q4 | -130.77 Thousand USD | 68.31% |
| 2015 FY | - USD | -112.58% |
| 2015 Q1 | -1.87 Million USD | -127.95% |
| 2014 FY | - USD | 4.97% |
| 2014 Q4 | 6.71 Million USD | 26.85% |
| 2014 Q1 | 4.75 Million USD | -2.54% |
| 2014 Q2 | 2.93 Million USD | -38.2% |
| 2014 Q3 | 5.29 Million USD | 80.23% |
| 2013 Q3 | 5.02 Million USD | 99.91% |
| 2013 Q1 | 6.46 Million USD | -11.17% |
| 2013 FY | - USD | -36.01% |
| 2013 Q4 | 4.87 Million USD | -2.95% |
| 2013 Q2 | 2.51 Million USD | -61.12% |
| 2012 Q4 | 7.28 Million USD | -2.67% |
| 2012 FY | - USD | 30.96% |
| 2012 Q3 | 7.48 Million USD | -0.61% |
| 2012 Q2 | 7.52 Million USD | 13.44% |
| 2012 Q1 | 6.63 Million USD | -7.31% |
| 2011 Q1 | 6 Million USD | 5645.61% |
| 2011 Q2 | 5.41 Million USD | -9.8% |
| 2011 Q3 | 4.63 Million USD | -14.33% |
| 2011 Q4 | 7.15 Million USD | 54.33% |
| 2011 FY | - USD | 93.34% |
| 2010 Q2 | 6.46 Million USD | 40.28% |
| 2010 FY | - USD | 4.77% |
| 2010 Q1 | 4.6 Million USD | 5.37% |
| 2010 Q4 | 104.49 Thousand USD | -75.95% |
| 2010 Q3 | 434.52 Thousand USD | -93.28% |
| 2009 Q3 | 799.16 Thousand USD | -85.84% |
| 2009 Q2 | 5.64 Million USD | 7820.46% |
| 2009 FY | - USD | 27.04% |
| 2009 Q4 | 4.37 Million USD | 447.04% |
| 2009 Q1 | 71.27 Thousand USD | 102.58% |
| 2008 FY | - USD | -53.55% |
| 2008 Q4 | -2.76 Million USD | -154.91% |
| 2008 Q3 | 5.02 Million USD | 15.13% |
| 2008 Q2 | 4.36 Million USD | 91.83% |
| 2008 Q1 | 2.27 Million USD | -48.18% |
| 2007 Q1 | 3.73 Million USD | 1497.98% |
| 2007 FY | - USD | 474.33% |
| 2007 Q4 | 4.39 Million USD | 1.24% |
| 2007 Q3 | 4.33 Million USD | -29.55% |
| 2007 Q2 | 6.15 Million USD | 64.97% |
| 2006 Q1 | 1.12 Million USD | -26.19% |
| 2006 Q2 | 898.75 Thousand USD | -20.08% |
| 2006 Q3 | 215.83 Thousand USD | -75.99% |
| 2006 Q4 | 233.64 Thousand USD | 8.25% |
| 2006 FY | - USD | -48.29% |
| 2005 Q2 | 1.16 Million USD | 938.31% |
| 2005 Q3 | 1.48 Million USD | 27.38% |
| 2005 Q4 | 1.52 Million USD | 2.47% |
| 2005 Q1 | 112.42 Thousand USD | 147.63% |
| 2005 FY | - USD | 35.7% |
| 2004 Q3 | 489.51 Thousand USD | -71.49% |
| 2004 Q4 | 45.4 Thousand USD | -90.73% |
| 2004 FY | - USD | -49.14% |
| 2004 Q1 | 2.3 Million USD | -4.39% |
| 2004 Q2 | 1.71 Million USD | -25.48% |
| 2003 Q1 | 2.13 Million USD | 54.31% |
| 2003 FY | - USD | 61.76% |
| 2003 Q4 | 2.4 Million USD | 117.95% |
| 2003 Q3 | 827.55 Thousand USD | -66.98% |
| 2003 Q2 | 3.34 Million USD | 57.12% |
| 2002 FY | - USD | -1.77% |
| 2002 Q4 | 1.38 Million USD | 15.82% |
| 2002 Q3 | 1.19 Million USD | -31.13% |
| 2002 Q2 | 1.73 Million USD | 22.33% |
| 2002 Q1 | 1.41 Million USD | -9.68% |
| 2001 Q1 | 1.48 Million USD | 258.94% |
| 2001 FY | - USD | 10.94% |
| 2001 Q4 | 1.56 Million USD | 41.55% |
| 2001 Q3 | 1.1 Million USD | -25.55% |
| 2001 Q2 | 1.48 Million USD | -9.76% |
| 2000 Q2 | 1.24 Million USD | -5.2% |
| 2000 Q1 | 2.06 Million USD | 19.56% |
| 2000 FY | - USD | -23.71% |
| 2000 Q4 | -1.03 Million USD | -145.64% |
| 2000 Q3 | 2.27 Million USD | 16.03% |
| 1999 Q4 | 1.72 Million USD | -23.25% |
| 1999 Q2 | 1.63 Million USD | 45.34% |
| 1999 Q1 | 1.12 Million USD | -30.21% |
| 1999 FY | - USD | 131.37% |
| 1999 Q3 | 2.25 Million USD | 37.46% |
| 1998 FY | - USD | 13.11% |
| 1998 Q4 | 1.61 Million USD | 305.36% |
| 1998 Q2 | 612.61 Thousand USD | -62.19% |
| 1998 Q1 | 1.62 Million USD | 0.0% |
| 1998 Q3 | -786.11 Thousand USD | -228.32% |
| 1997 Q3 | 496.8 Thousand USD | -31.74% |
| 1997 FY | - USD | 83.41% |
| 1997 Q2 | 727.82 Thousand USD | 69.58% |
| 1997 Q1 | 429.18 Thousand USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aurora Cannabis Inc. | 20.47 Million CAD | 37.071% |
| Avicanna Inc. | -7.35 Million CAD | 275.162% |
| Avant Brands Inc. | 4.83 Million CAD | -166.419% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | 146.212% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | -28531.111% |
| Knight Therapeutics Inc. | 40.89 Million CAD | 68.496% |
| MediPharm Labs Corp. | -10.47 Million CAD | 222.962% |
| OrganiGram Holdings Inc. | -207.61 Million CAD | 106.206% |
| Canopy Growth Corporation | -312.82 Million CAD | 104.119% |
| Willow Biosciences Inc. | -11.06 Million CAD | 216.481% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | 219.021% |